BioSpace News Archive

Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a clinical trial to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with palbocic

Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced that it had launched the revolutionary Chronos Automated Binocular Refraction System with SightPilot® guided refraction software.

A research team led by Professor Wang Wen-ching of the Institute of Molecular and Cellular Biology, National Tsing Hua University (NTHU) has exploited the power of big data to identify two key biomarkers contributing to the proliferation and metastasis of gastric (stomach) cancer.

Agenus Inc. announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and COO of Agenus, and Dr. Dhan Chand, Scientific Director Head of Drug Discovery at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Monday, November 16, 2020 at 10:00 a.m. ET.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2020, as well as recent business updates.

BIOLASE, Inc., the global leader in dental lasers, announced it has been invited to participate in the Benchmark Company Discovery One on One Investor Conference on November 18, 2020.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on January 5, 2021 to all shareholders of record as of December 15, 2020.

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company’s novel Cellspan™ technology for the treatment of esophageal atresia and esophageal disease, today announced its financial results for the three and nine months ended September 30, 2020.

Annual incidence of accidental exposures resulting in allergic reactions is more than 10% in peanut-allergic children, highlighting the need for successful desensitization therapies and tools to confirm their effectiveness.